Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Shanghai Fosun Pharmaceutical Group
Pharma
Eisai, GSK, Daiichi Sankyo—Fierce Pharma Asia
Eisia's lecanemab phase 3 had one patient death. China suspends GSK from volume-based procurement. Daiichi increases its Enhertu sales projection.
Angus Liu
Nov 4, 2022 9:00am
Henlius CEO scouts for US PD-1 partner amid Fosun unit's pivot
Aug 30, 2022 1:30am
Takeda-Denali, Daiichi Sankyo, J&J-Legend—Fierce Pharma Asia
Jan 14, 2022 9:15am
China's NRDL, Biocon-Viatris and more—Fierce Pharma Asia
Dec 10, 2021 8:45am
Biogen, Pfizer, Lilly and more win China NRDL coverage
Dec 3, 2021 10:15am
BioNTech, Takeda, AZ-Daiichi and more—Fierce Pharma Asia
May 14, 2021 4:01am
